FDA Approves Cell Therapy for Blood Cancer Patients

Cell therapy has the potential to reduce the risk of infection after stem cell transplants. The U.S. Food and Drug Administration (FDA) recently approved Omisirge (omidubicel-onlv), a donor-modified…

Read More

FDA’s Plasma Program Data Lacks Cohesion

¬†Informal study hampered by greater than anticipated participation of COVID-19 patients. The U.S. Food and Drug Administration designed a plasma program to try and speed along potential research…

Read More
Back to top
FE3